Immunotherapy: Open Access
Open Access
ISSN: 2471-9552
ISSN: 2471-9552
Manal Mohamed Saber and Matthias Clauss
Minia University, Egypt
Indiana University School of Medicine, Indianapolis, Indiana
Scientific Tracks Abstracts: Immunotherapy (Los Angel)
Statement of the Problem: Colorectal cancer (CRC) is being currently considered one of the most common and deadly malignancies in the world. Many CRC patients are likely to be immunosuppressive. Endothelial monocyte-activating polypeptide-II (EMAP-II) is a multifunctional cytokine with pro-inflammatory properties. It was demonstrated that EMAP-II induces lymphocytes apoptosis in CRC. The purpose of this study is to investigate the role of EMAP II in immune suppression in CRC. Methodology & Theoretical Orientation: The immunosuppressive effect of EMAP-II was verified by in vivo and in vitro experiments. The immunosuppressive mechanisms were analysed using flow cytometry, ELISA, immunohistochemistry and T-lymphocytes assays. Findings: EMAP-II expression in CRC was associated with suppression of T-cell activity and decreased infiltrating T-cells. EMAP-II blockade in mice bearing colorectal cancer reduced tumour burden and increased T-cell responses. In this study, we found that colorectal cancer-infiltrating tregs expressed increased levels of EMAP-II. Furthermore, EMAP-II levels correlated positively with serum IL-2 and TGF-�² (p<0.001). Conclusion & Significance: This study has demonstrated the role of EMAP-II in immune suppression and the potential for immunotherapy via blocking EMAP-II in CRC.
Manal Mohamed Saber has completed her PhD from Nottingham University, UK. She is an Associate Professor of Clinical Pathology, Minia University, Egypt. She has published papers in peer reviewed journals and has been serving as an Editorial Board Member of others. She has interests in cancer studies, immunotherapy and tumor immunology
Email: manal.saber@mu.edu.eg